Skip to main content
Erschienen in: Esophagus 1/2021

08.06.2020 | Original Article

Influence of preoperative chemotherapy-induced leukopenia on survival in patients with esophageal squamous cell carcinoma: exploratory analysis of JCOG9907

verfasst von: Hiroki Hara, Junki Mizusawa, Shuichi Hironaka, Ken Kato, Hiroyuki Daiko, Tetsuya Abe, Kenichi Nakamura, Nobutoshi Ando, Yuko Kitagawa

Erschienen in: Esophagus | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

The relationship between chemotherapy-induced leukopenia (CIL) and survival has not been investigated in patients undergoing preoperative chemotherapy for esophageal squamous cell carcinoma (ESCC). We analyzed the association of CIL with survival outcomes using data from JCOG9907 on the efficacy of preoperative chemotherapy for stage II/III ESCC.

Methods

Preoperative chemotherapy consisted of two courses of 5-FU (800 mg/m2 days 1–5) and cisplatin (80 mg/m2 day 1) repeated every 3 weeks. Patients in the preoperative chemotherapy arm receiving at least one course of chemotherapy and undergoing subsequent surgery in JCOG9907 were divided into two subgroups: CIL ( +), those with grade 2–4 leukopenia at least once during preoperative chemotherapy; and CIL (−), those with grades 0–1. The association of CIL with overall survival (OS) and progression-free survival (PFS) was analyzed.

Results

Among 164 patients enrolled in JCOG9907, 152 patients were included in this analysis, 52 in CIL ( +) and 100 patients in CIL (−) subgroups. The 3-year OS for CIL ( +) was inferior to that for CIL (−) (48.1% vs. 73.9%); hazard ratio (HR) = 1.94 (95% CI 1.18–3.16, P < .01). For 3-year PFS, a similar tendency was observed (44.2% vs. 55.8%; HR = 1.38 (95% CI 0.88–2.17, P = .16). Multivariable analysis revealed that CIL was not an independent factor for OS (HR = 1.14, 95% CI 0.63–2.07, P = .67).

Conclusion

We showed that CIL during preoperative chemotherapy might not be a prognostic factor in patients with ESCC.
Literatur
1.
Zurück zum Zitat Fitzmaurice C, Dicker D, Pain A, et al. The Global Burden of Cancer 2013. JAMA Oncol. 2015;1(4):505–27.PubMedCrossRef Fitzmaurice C, Dicker D, Pain A, et al. The Global Burden of Cancer 2013. JAMA Oncol. 2015;1(4):505–27.PubMedCrossRef
2.
Zurück zum Zitat Vital Statistics in Japan (Ministry of Health, Labour and Welfare) 2015. Vital Statistics in Japan (Ministry of Health, Labour and Welfare) 2015.
4.
Zurück zum Zitat Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19(1):68–74.PubMed Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19(1):68–74.PubMed
5.
Zurück zum Zitat Shitara K, Matsuo K, Takahari D, et al. Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX. Eur J Cancer. 2009;45(10):1757–63.PubMedCrossRef Shitara K, Matsuo K, Takahari D, et al. Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX. Eur J Cancer. 2009;45(10):1757–63.PubMedCrossRef
6.
Zurück zum Zitat Shitara K, Matsuo K, Takahari D, et al. Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel. Ann Oncol. 2010;21(12):2403–9.PubMedCrossRef Shitara K, Matsuo K, Takahari D, et al. Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel. Ann Oncol. 2010;21(12):2403–9.PubMedCrossRef
7.
Zurück zum Zitat Koutras AK, Fountzilas G, Dafni U, et al. Myelotoxicity as a prognostic factor in patients with advanced breast cancer treated with chemotherapy: a pooled analysis of two randomised trials conducted by the Hellenic cooperative oncology group. Anticancer Res. 2008;28(5b):2913–20.PubMed Koutras AK, Fountzilas G, Dafni U, et al. Myelotoxicity as a prognostic factor in patients with advanced breast cancer treated with chemotherapy: a pooled analysis of two randomised trials conducted by the Hellenic cooperative oncology group. Anticancer Res. 2008;28(5b):2913–20.PubMed
8.
Zurück zum Zitat Miyoshi N, Yano M, Takachi K, et al. Myelotoxicity of preoperative chemoradiotherapy is a significant determinant of poor prognosis in patients with T4 esophageal cancer. J Surg Oncol. 2009;99(5):302–6.PubMedCrossRef Miyoshi N, Yano M, Takachi K, et al. Myelotoxicity of preoperative chemoradiotherapy is a significant determinant of poor prognosis in patients with T4 esophageal cancer. J Surg Oncol. 2009;99(5):302–6.PubMedCrossRef
9.
Zurück zum Zitat Kim JJ, Park JY, Kim DY, et al. Is chemotherapy-induced neutropenia a prognostic factor in patients with ovarian cancer? Acta Obstet Gynecol Scand. 2010;89(5):623–8.PubMedCrossRef Kim JJ, Park JY, Kim DY, et al. Is chemotherapy-induced neutropenia a prognostic factor in patients with ovarian cancer? Acta Obstet Gynecol Scand. 2010;89(5):623–8.PubMedCrossRef
10.
Zurück zum Zitat Ohira M, Kubo N, Yamashita Y, et al. Impact of chemoradiation-induced myelosuppression on prognosis of patients with locally advanced esophageal cancer after chemoradiotherapy followed by esophagectomy. Anticancer Res. 2015;35(9):4889–955.PubMed Ohira M, Kubo N, Yamashita Y, et al. Impact of chemoradiation-induced myelosuppression on prognosis of patients with locally advanced esophageal cancer after chemoradiotherapy followed by esophagectomy. Anticancer Res. 2015;35(9):4889–955.PubMed
11.
Zurück zum Zitat Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000;47(1):13–47.PubMedCrossRef Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000;47(1):13–47.PubMedCrossRef
12.
Zurück zum Zitat Shitara K, Matsuo K, Oze I, et al. Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy. Cancer Chemother Pharmacol. 2011;68(2):301–7.PubMedCrossRef Shitara K, Matsuo K, Oze I, et al. Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy. Cancer Chemother Pharmacol. 2011;68(2):301–7.PubMedCrossRef
13.
Zurück zum Zitat Bogani G, Sabatucci I, Maltese G, et al. Chemotherapy-related leukopenia as a biomarker predicting survival outcomes in locally advanced cervical cancer. Eur J Obstet Gynecol Reprod Biol. 2017;208:41–5.PubMedCrossRef Bogani G, Sabatucci I, Maltese G, et al. Chemotherapy-related leukopenia as a biomarker predicting survival outcomes in locally advanced cervical cancer. Eur J Obstet Gynecol Reprod Biol. 2017;208:41–5.PubMedCrossRef
14.
Zurück zum Zitat Yokota T, Ando N, Igaki H, et al. Prognostic factors in patients receiving neoadjuvant 5-fluorouracil plus cisplatin for advanced esophageal cancer (JCOG9907). Oncology. 2015;89(3):143–51.PubMedCrossRef Yokota T, Ando N, Igaki H, et al. Prognostic factors in patients receiving neoadjuvant 5-fluorouracil plus cisplatin for advanced esophageal cancer (JCOG9907). Oncology. 2015;89(3):143–51.PubMedCrossRef
15.
Zurück zum Zitat Kurokawa Y, Shibata T, Ando N, Seki S, Mukaida H, Fukuda H. Which is the optimal response criteria for evaluating preoperative treatment in esophageal cancer: RECIST or histology? Ann Surg Oncol. 2013;20(9):3009–144.PubMedCrossRef Kurokawa Y, Shibata T, Ando N, Seki S, Mukaida H, Fukuda H. Which is the optimal response criteria for evaluating preoperative treatment in esophageal cancer: RECIST or histology? Ann Surg Oncol. 2013;20(9):3009–144.PubMedCrossRef
16.
Zurück zum Zitat Meredith KL, Weber JM, Turaga KK, et al. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. Ann Surg Oncol. 2010;17(4):1159–67.PubMedCrossRef Meredith KL, Weber JM, Turaga KK, et al. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. Ann Surg Oncol. 2010;17(4):1159–67.PubMedCrossRef
17.
Zurück zum Zitat Nakamura K, Kato K, Igaki H, et al. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study). Jpn J Clin Oncol. 2013;43(7):752–5.PubMedCrossRef Nakamura K, Kato K, Igaki H, et al. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study). Jpn J Clin Oncol. 2013;43(7):752–5.PubMedCrossRef
Metadaten
Titel
Influence of preoperative chemotherapy-induced leukopenia on survival in patients with esophageal squamous cell carcinoma: exploratory analysis of JCOG9907
verfasst von
Hiroki Hara
Junki Mizusawa
Shuichi Hironaka
Ken Kato
Hiroyuki Daiko
Tetsuya Abe
Kenichi Nakamura
Nobutoshi Ando
Yuko Kitagawa
Publikationsdatum
08.06.2020
Verlag
Springer Singapore
Erschienen in
Esophagus / Ausgabe 1/2021
Print ISSN: 1612-9059
Elektronische ISSN: 1612-9067
DOI
https://doi.org/10.1007/s10388-020-00752-7

Weitere Artikel der Ausgabe 1/2021

Esophagus 1/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.